Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.51 |
| ▸ | SRC | P12931 | 5/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730436 | 1.00 | PDE4B (0.51) | PDE4BSRCFYNCYP2D6TSHR | |
| SCHEMBL729253 | 0.99 | PDE4B (0.51) | PDE4BSRCFYNCYP2D6TSHR | |
| SCHEMBL730552 | 0.97 | PDE4B (0.50) | PDE4BSRCFYNCYP2D6TSHR | |
| SCHEMBL722798 | 0.92 | PDE4B (0.53) | PDE4BSRCFYNABL1BCR | |
| SCHEMBL729216 | 0.92 | PDE4B (0.53) | PDE4BSRCFYNABL1BCR | |
| SCHEMBL730860 | 0.92 | PDE4B (0.53) | PDE4BSRCFYNABL1BCR | |
| SCHEMBL730531 | 0.92 | PDE4B (0.53) | PDE4BSRCFYNABL1BCR | |
| SCHEMBL12729827 | 0.92 | TSHR (0.48) | PDE4BSRCFYNCYP2D6TSHR | |
| SCHEMBL730443 | 0.91 | PDE4B (0.50) | PDE4BSRC | |
| SCHEMBL728837 | 0.91 | PDE4B (0.50) | PDE4BSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| EP-2482798-A1 | OLOPATADINE COMPOSITIONS AND USES THEREOF | Alcon Research, Ltd. (US) | 2012-08-08 | — | — | EP | claimed |
| EP-2467376-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Kalypsys, Inc. (US) | 2012-06-27 | — | — | EP | claimed |
| US-8138205-B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | KALYPSYS, INC. (US) | 2012-03-20 | — | — | US | claimed |
| WO-2011093924-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC (US) | 2011-08-04 | — | — | WO | claimed |
| US-20110082145-A1 | OLOPATADINE COMPOSITIONS AND USES THEREOF | ALCON RESEARCH, LTD. (US) | 2011-04-07 | — | — | US | claimed |
| WO-2011041640-A1 | OLOPATADINE COMPOSITIONS AND USES THEREOF | ALCON RESEARCH, LTD. (US) | 2011-04-07 | — | — | WO | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | disclosed |
| US-11833141-B2 | Topical formulations and compositions | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-12-05 | — | — | US | disclosed |
| WO-2023144614-A1 | NASAL COMPOSITIONS AND METHODS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-08-03 | — | — | WO | disclosed |
| US-20230020927-A1 | TOPICAL FORMULATIONS AND COMPOSITIONS | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-01-19 | — | — | US | disclosed |
| US-20110082145-A1 | OLOPATADINE COMPOSITIONS AND USES THEREOF | ALCON RESEARCH, LTD. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041640-A1 | OLOPATADINE COMPOSITIONS AND USES THEREOF | ALCON RESEARCH, LTD. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082145-A1 | OLOPATADINE COMPOSITIONS AND USES THEREOF | PDE4B, PDE4A, PDE4C | PDE4B 1/4885SRC 4168/4885FYN 2092/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE4B 1894/4885SRC 4811/4885FYN 4152/4885 |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885SRC 3951/4885FYN 2070/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE4B 1894/4885SRC 4811/4885FYN 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.